Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | LTA4H | P09960 | 2/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256041 | 0.90 | LTA4H (0.61) | L3MBTL1LTA4HFFAR1KDM4ESMN1; SMN2 | |
| SCHEMBL4401690 | 0.89 | PPARA (0.63) | L3MBTL1LTA4HFFAR1KDM4ESMN1; SMN2 | |
| SCHEMBL1008370 | 0.87 | PPARA (0.61) | L3MBTL1LTA4HFFAR1KDM4ESMN1; SMN2 | |
| SCHEMBL4654976 | 0.87 | PPARA (0.61) | L3MBTL1LTA4HFFAR1KDM4ESMN1; SMN2 | |
| SCHEMBL4654038 | 0.87 | PPARA (0.61) | L3MBTL1LTA4HFFAR1KDM4ESMN1; SMN2 | |
| SCHEMBL8863703 | 0.87 | PPARA (0.61) | L3MBTL1LTA4HFFAR1KDM4ESMN1; SMN2 | |
| SCHEMBL7566062 | 0.83 | PPARA (0.69) | LTA4HFFAR1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL8302869 | 0.82 | LTA4H (0.54) | L3MBTL1LTA4HKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL19043168 | 0.82 | PARP10 (0.51) | L3MBTL1LTA4HKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1310073 | 0.82 | LTA4H (0.50) | L3MBTL1LTA4HKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | claimed |
| EP-0168006-B1 | PROCESS FOR PREPARING 3-(4-FLUOROPHENOXY)PROPIONITRILE AND A PROCESS FOR PREPARING 6-FLUORO-4-CHROMANONE USING 3-(4-FLUOROPHENOXY)PROPIONITRILE | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-12-27 | — | — | EP | claimed |
| EP-0168006-A2 | Process for preparing 3-(4-Fluorophenoxy)propionitrile and a process for preparing 6-fluoro-4-chromanone using 3-(4-fluorophenoxy)propionitrile | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-01-15 | — | — | EP | claimed |
| JP-62215548-A | — | — | None | — | — | JP | disclosed |
| JP-62126184-A | — | — | None | — | — | JP | disclosed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| US-20240027902-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| US-4177282-A | ANITDIABETIC | PFIZER INC. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4130714-A | SPIRO CHROMANS OR THIOCHROMANS | PFIZER INC. (US) | 1978-12-19 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4086240-A | 1-Thiazolyl-5-phenoxy and phenylthioalkanoyloxyimidazolidinones | VELSICOL CHEMICAL CORPORATION (US) | 1978-04-25 | — | — | US | disclosed |
| US-4053480-A | 1-THIADIAZOLYL-5-PHENOXY- AND PHENYLTHIOALKANOYLOXY IMIDAZOLIDINONES | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | L3MBTL1 3878/4885LTA4H 2152/4885MMP2 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.